Search Results - "Milgram, Laura J.H."

Asthma medications should be available for over-the-counter use: con by Milgram, Laura J H

“…The United States Food and Drug Administration recently considered a policy to transfer inhaled short-acting bronchodilators to over-the-counter status if…”
Get full text

Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution by Konstan, Michael W, Davis, Pamela B, Wagener, Jeffrey S, Hilliard, Kathleen A, Stern, Robert C, Milgram, Laura J H, Kowalczyk, Tomasz H, Hyatt, Susannah L, Fink, Tamara L, Gedeon, Christopher R, Oette, Sharon M, Payne, Jennifer M, Muhammad, Osman, Ziady, Assem G, Moen, Robert C, Cooper, Mark J

“…A double-blind, dose escalation gene transfer trial was conducted in subjects with cystic fibrosis (CF), among whom placebo (saline) or compacted DNA was…”
Get more information

Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials by Standaert, Thomas A., Boitano, Louis, Emerson, Julia, Milgram, Laura J.H., Konstan, Michael W., Hunter, Janice, Berclaz, Pierre-Yves, Brass, Lois, Zeitlin, Pamela L., Hammond, Keith, Davies, Zoe, Foy, Carla, Noone, Peadar G., Knowles, Michael R.

“…Patients with cystic fibrosis (CF) can be discriminated from healthy subjects by measurement of the nasal potential difference, which has become a useful…”
Get full text

In vivo Activation of the Cystic Fibrosis Transmembrane Conductance Regulator Mutant Δ F508 in Murine Nasal Epithelium by Kelley, Thomas J., Thomas, Kirk, Laura J. H. Milgram, Drumm, Mitchell L.

“…The gene causing cystic fibrosis (CF) encodes the CF transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel. Mutations in this gene…”
Get full text

Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis by Ahrens, Richard C., Standaert, Thomas A., Launspach, Janice, Han, Seung-Ho, Teresi, Mary E., Aitken, Moira L., Kelley, Thomas J., Hilliard, Kathleen A., Milgram, Laura J.H., Konstan, Michael W., Weatherly, Mark R., McCarty, Nael A.

“…One of the goals of current research in cystic fibrosis (CF) is to develop treatments that correct or compensate for defects in function of the cystic fibrosis…”
Get full text

A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis by McCarty, Nael A., Standaert, Thomas A., Teresi, Mary, Tuthill, Cynthia, Launspach, Janice, Kelley, Thomas J., Milgram, Laura J.H., Hilliard, Kathleen A., Regelmann, Warren E., Weatherly, Mark R., Aitken, Moira L., Konstan, Michael W., Ahrens, Richard C.

“…CPX (8‐cyclopentyl‐1,3‐dipropylxanthine) is a novel compound currently under development as a potential treatment for cystic fibrosis (CF). The drug has been…”
Get full text